Because GLP-1s can impact how your digestive system works, they often cause a few gastrointestinal (GI) side effects
Phase 3 studies are underway to confirm the full safety profile of retatrutide
The care model is intentionally streamlined: onboarding takes minutes, prescriptions are processed quickly, auto-refills are built in, and dose adjustments follow a simple escalation pathway
In cell-based assays retatrutide is deliberately unbalanced relative to the native hormones about 0.4 times as active at the GLP-1 receptor, 0.3 times as active at the glucagon receptor and roughly 8.9 times as active at the GIP receptor so GIP signalling carries the most weight while the glucagon arm stays measured [6]
Retatrutide is called a triple G drug because it targets three different hormone receptors at the same time: GLP-1, GIP, and glucagon
Patients should be particularly cautious about any product marketed as retatrutide through online or informal channels